On January 16, 2025, Deloitte China proudly announced the "2024 Deloitte China High Tech Growth 50 Strong" (referred to as "China 50 Strong") and "Deloitte China Rising Stars" (referred to as "Rising Stars") lists.METiS TechBio (METiS Pharmaceuticals) has successfully been selected for the "Rising Stars" list, becoming one of the representative companies in the field, thanks to its outstanding innovation and development in AI and nanomaterials.The Deloitte Technology Fast Growing Companies Selection Project was founded in Silicon Valley, USA in 1995, entered China in 2005, and is held annually in dozens of countries and regions. Many industry leaders have emerged from the annual lists, such as: Tencent, Alibaba, Baidu, JD.com, SMIC, WuXi AppTec, ByteDance, Apple, Microsoft, Google, Tesla, NVIDIA, etc. Companies on the list are usually at an early stage when selected, and the list is also known as the "Cradle of Great Technology Companies."
In this year's "Rising Stars" list, the life sciences field accounted for 42% of the total, becoming the biggest highlight.Following closely behind are hardware (22%), software (12%), and the internet and high-end equipment (each accounting for 10%). At the same time, the report shows that more than half of the "Top 50 in China" and "Tomorrow's Stars" enterprises are prioritizing artificial intelligence and machine learning as their main investment areas. Emerging technologies such as cloud computing, big data, robotics, and automation have also become important fields for future development.METiS TechBio, as a representative company in the AI + nanomaterials field, has successfully developed groundbreaking artificial intelligence and computational simulation algorithms for ionizable lipid generation and design, LNP (lipid nanoparticle) design and simulation, overcoming the dual challenges of data scarcity and unprecedented algorithms through innovative breakthroughs.The company has combined world-leading high-throughput experimental technology with an animal validation platform, building a strong data and algorithm barrier, and achieved breakthrough progress in the field of nanomaterial design and drug delivery.Moreover, by integrating the rapidly advancing large models and generative AI technologies, METiS TechBioMETiS TechBio Established the World's First METiS LipidLM Lipid Language Model and PhatGPT Lipid Generation Model, SuccessfullyBuild a million-level lipid library and break through international patent barriers. At the same time, METiS TechBio combines innovative molecular simulation technology to simulate various microscopic processes of LNP in vivo and in vitro, relying on a world-class experimental validation platform.Empowering the development of multi-organ targeted nanomaterials, achieving the successful implementation of AI + nanomaterial applications.Looking ahead, METiS TechBio will continue to deepen its AI technology platform, promote the development of the pharmaceutical ecosystem, and explore broader AI application scenarios, particularly in the intelligent design of nanomaterials and efficient drug delivery. The company will remain committed to technology-driven innovation, striving to bring more breakthrough treatment options to patients worldwide and support the high-quality development of the biopharmaceutical industry.AttachmentDeloitte China Tomorrow's Star List
Can scroll up and down to read
Learn More About METiS TechBio
